Secondary resistance in oral treatment of diabetes.
作者信息
DOTEVALL G
出版信息
Acta Med Scand. 1958 Jun 9;161(3):251-6. doi: 10.1111/j.0954-6820.1958.tb15542.x.
Abstract
摘要
相似文献
1
Secondary resistance in oral treatment of diabetes.
Acta Med Scand. 1958 Jun 9;161(3):251-6. doi: 10.1111/j.0954-6820.1958.tb15542.x.
2
[Personal experience in treatment of diabetes by oral administration of BZ 55].
Rev Clin Esp. 1956 Jul 31;62(2):81-7.
3
[Sucontral for oral administration in therapy of diabetes].
Med Hyg (Geneve). 1952 Dec 15;10(232):504.
4
[Oral treatment of diabetes mellitus with a sulfonamide derivative; N1-sulfanilyn-N2-n-butyl carbamide].
Minerva Med. 1956 Jun 23;47(50):1968-75.
5
[Oral treatment of diabetes mellitus with N-4-methyl-benzolsulfonyl-N'-butyl-urea (D-860); clinical and experimental research].
Dtsch Med Wochenschr. 1956 Jun 1;81(22):887-960; concl.
6
Editorial: Oral therapy in diabetes mellitus--an update.
South Med J. 1976 Jun;69(6):679-81. doi: 10.1097/00007611-197606000-00002.
7
[Uses of BZ 55: a sulfonamide derivative for oral administration].
Dia Med. 1956 Jun 25;28(43):1205-16.
8
[A new anti-diabetic principle for oral administration].
Rev Bras Med. 1956 Apr;13(4):267-8.
9
The role of carbohydrate and oral agents in the treatment of diabetes mellitus.
Calif Med. 1973 Oct;119(4):37-47.
10
[Cell therapy and gene therapy in diabetes mellitus].
MMW Fortschr Med. 2004 May 13;146(20):39-40.
引用本文的文献
1
Oral Treatment of Diabetes Mellitus.
Br Med J. 1961 Jan 21;1(5220):188-9.
2
Carbutamide in diabetes: report of a long-term trial, with special reference to late failures.
Br Med J. 1960 Apr 9;1(5179):1089-91. doi: 10.1136/bmj.1.5179.1089.
Zotero 插件